Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/52537
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss
Author: Diamond, P.
Labrinidis, A.
Martin, S.
Farrugia, A.
Gronthos, S.
To, L.
Fujii, N.
O'Loughlin, P.
Evdokiou, A.
Zannettino, A.
Citation: Journal of Bone and Mineral Research, 2009; 24(7):1150-1161
Publisher: Amer Soc Bone & Mineral Res
Issue Date: 2009
ISSN: 0884-0431
1523-4681
Statement of
Responsibility: 
Peter Diamond, Agatha Labrinidis, Sally K Martin, Amanda N Farrugia, Stan Gronthos, L Bik To, Nobutaka Fujii, Peter D O'Loughlin, Andreas Evdokiou and Andrew CW Zannettino
Abstract: The plasma cell (PC) malignancy, multiple myeloma (MM), is unique among hematological malignancies in its capacity to cause osteoclast (OC)-mediated skeletal destruction. We have previously shown that elevated plasma levels of PC-derived CXCL12 are associated with presence of X-ray detectable osteolytic lesions in MM patients. To further investigate this relationship, plasma levels of CXCL12 and βCrossLaps, a marker of bone loss, were measured. A strong correlation between levels of CXCL12 and OC-mediated bone resorption was identified. To confirm the OC-activating potential of MM PC-derived CXCL12 in vivo, we established a model of MM-mediated focal osteolysis, wherein MM PC lines, such as RPMI-8226, were injected into the tibias of nude mice. Implanting RPMI-8226 gave rise to osteolytic lesions proximal to the tumor, resulting in a 5% decrease in bone volume (BV) compared with vehicle control. Importantly, bone loss was significantly inhibited with systemic administration of the CXCL12/CXCR4 antagonist T140. Furthermore, implanting CXCL12-overexpressing RPMI-8226 cells resulted in a 13% decrease in BV and was associated with increased OC recruitment proximal to the tumor, increased serum matrix metalloproteinase activity, and increased levels of collagen I degradation products. These findings confirm our hypothesis that MM PC-derived CXCL12 stimulates the recruitment and activity of OC, thereby contributing to the formation of MM osteolytic lesions.
Keywords: multiple myeloma; stromal-derived factor-1α; CXCL12; osteolysis
RMID: 0020090988
DOI: 10.1359/JBMR.090210
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.